mephtazolol

Mephtazolol is a novel small molecule analgesic developed by Shandong Taitian New Drug Development for the management of moderate to severe pain, specifically postoperative pain. Chemically, it is a derivative of meptazinol and is classified as a Class 1.1 new drug in China. Mephtazolol primarily functions as an opioid receptor agonist, likely targeting the mu-opioid receptor to provide analgesic effects. Clinical development has focused on its use as an oral tablet for short-term treatment of moderate pain following orthopedic surgery, where it has been evaluated in Phase II trials (e.g., CTR20150566) against active comparators such as tramadol.

Other names

mephtazolol hydrochloride美他唑醇